van Genugten ML - Search Results

1

Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults.

Postma MJ, Jansema P, Scheijbeler HW, van Genugten ML. Postma MJ, et al. Among authors: van genugten ml. Vaccine. 2005 Nov 16;23(46-47):5365-71. doi: 10.1016/j.vaccine.2005.06.007. Epub 2005 Jul 1. Vaccine. 2005. PMID: 16029916

2

Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Postma MJ, Jansema P, van Genugten ML, Heijnen ML, Jager JC, de Jong-van den Berg LT. Postma MJ, et al. Among authors: van genugten ml. Drugs. 2002;62(7):1013-24. doi: 10.2165/00003495-200262070-00003. Drugs. 2002. PMID: 11985488 Review.

3

Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands.

Postma MJ, Novak A, Scheijbeler HW, Gyldmark M, van Genugten ML, Wilschut JC. Postma MJ, et al. Among authors: van genugten ml. Pharmacoeconomics. 2007;25(6):497-509. doi: 10.2165/00019053-200725060-00005. Pharmacoeconomics. 2007. PMID: 17523754

4

Future costs of stroke in the Netherlands: the impact of stroke services.

Struijs JN, van Genugten ML, Evers SM, Ament AJ, Baan CA, van den Bos GA. Struijs JN, et al. Among authors: van genugten ml. Int J Technol Assess Health Care. 2006 Fall;22(4):518-24. doi: 10.1017/S0266462306051464. Int J Technol Assess Health Care. 2006. PMID: 16984687

5

Pandemic influenza and healthcare demand in the Netherlands: scenario analysis.

van Genugten ML, Heijnen ML, Jager JC. van Genugten ML, et al. Emerg Infect Dis. 2003 May;9(5):531-8. doi: 10.3201/eid0905.020321. Emerg Infect Dis. 2003. PMID: 12737735 Free PMC article.

6

The expected number of hospitalisations and beds needed due to pandemic influenza on a regional level in the Netherlands.

van Genugten ML, Heijnen ML. van Genugten ML, et al. Virus Res. 2004 Jul;103(1-2):17-23. doi: 10.1016/j.virusres.2004.02.007. Virus Res. 2004. PMID: 15163483

7

Future burden and costs of smoking-related disease in the Netherlands: a dynamic modeling approach.

van Genugten ML, Hoogenveen RT, Mulder I, Smit HA, Jansen J, de Hollander AE. van Genugten ML, et al. Value Health. 2003 Jul-Aug;6(4):494-9. doi: 10.1046/j.1524-4733.2003.64157.x. Value Health. 2003. PMID: 12859591 Free article.

8

International comparison of stroke cost studies.

Evers SM, Struijs JN, Ament AJ, van Genugten ML, Jager JH, van den Bos GA. Evers SM, et al. Among authors: van genugten ml. Stroke. 2004 May;35(5):1209-15. doi: 10.1161/01.STR.0000125860.48180.48. Epub 2004 Apr 8. Stroke. 2004. PMID: 15073405 Review.

9

Modeling the future burden of stroke in The Netherlands: impact of aging, smoking, and hypertension.

Struijs JN, van Genugten ML, Evers SM, Ament AJ, Baan CA, van den Bos GA. Struijs JN, et al. Among authors: van genugten ml. Stroke. 2005 Aug;36(8):1648-55. doi: 10.1161/01.STR.0000173221.37568.d2. Epub 2005 Jul 7. Stroke. 2005. PMID: 16002757

10

Costs and effects of prenatal screening methods for Down syndrome and neural tube defects.

Hoogendoorn M, Evers SM, Schielen PC, van Genugten ML, de Wit GA, Ament AJ. Hoogendoorn M, et al. Among authors: van genugten ml. Community Genet. 2008;11(6):359-67. doi: 10.1159/000133308. Epub 2008 Aug 5. Community Genet. 2008. PMID: 18690004

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

17 results

Search Page